Literature DB >> 30464055

SEC31A mutation affects ER homeostasis, causing a neurological syndrome.

Hagit Flusser1, Ohad S Birk2,3, Daniel Halperin2, Rotem Kadir2, Yonatan Perez2, Max Drabkin2, Yuval Yogev2, Ohad Wormser2, Erez M Berman2, Ekaterina Eremenko4, Barak Rotblat5, Zamir Shorer6, Libe Gradstein7, Ilan Shelef8, Ruth Birk9, Uri Abdu5.   

Abstract

BACKGROUND: Consanguineous kindred presented with an autosomal recessive syndrome of intrauterine growth retardation, marked developmental delay, spastic quadriplegia with profound contractures, pseudobulbar palsy with recurrent aspirations, epilepsy, dysmorphism, neurosensory deafness and optic nerve atrophy with no eye fixation. Affected individuals died by the age of 4. Brain MRI demonstrated microcephaly, semilobar holoprosencephaly and agenesis of corpus callosum. We aimed at elucidating the molecular basis of this disease.
METHODS: Genome-wide linkage analysis combined with whole exome sequencing were performed to identify disease-causing variants. Functional consequences were investigated in fruit flies null mutant for the Drosophila SEC31A orthologue. SEC31A knockout SH-SY5Y and HEK293T cell-lines were generated using CRISPR/Cas9 and studied through qRT-PCR, immunoblotting and viability assays.
RESULTS: Through genetic studies, we identified a disease-associated homozygous nonsense mutation in SEC31A. We demonstrate that SEC31A is ubiquitously expressed, and that the mutation triggers nonsense-mediated decay of its transcript, comprising a practical null mutation. Similar to the human disease phenotype, knockdown SEC31A flies had defective brains and early lethality. Moreover, in line with SEC31A encoding one of the two coating layers comprising the Coat protein complex II (COP-II) complex, trafficking newly synthesised proteins from the endoplasmic reticulum (ER) to the Golgi, CRISPR/Cas9-mediated SEC31A null mutant cells demonstrated reduced viability through upregulation of ER-stress pathways.
CONCLUSION: We demonstrate through human and Drosophila genetic and in vitro molecular studies, that a severe neurological syndrome is caused by a null mutation in SEC31A, reducing cell viability through enhanced ER-stress response, in line with SEC31A's role in the COP-II complex. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COP-II complex; Sec31A; genetic mutation; neurological syndrome

Mesh:

Substances:

Year:  2018        PMID: 30464055     DOI: 10.1136/jmedgenet-2018-105503

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  9 in total

1.  A novel homozygous mutation (p.N958K) of SLC12A3 in Gitelman syndrome is associated with endoplasmic reticulum stress.

Authors:  W Tang; X Huang; Y Liu; Q Lv; T Li; Y Song; X Zhang; X Chen; Y Shi
Journal:  J Endocrinol Invest       Date:  2020-07-08       Impact factor: 4.256

Review 2.  Consequences of mutations in the genes of the ER export machinery COPII in vertebrates.

Authors:  Chung-Ling Lu; Jinoh Kim
Journal:  Cell Stress Chaperones       Date:  2020-01-22       Impact factor: 3.667

3.  Involvement of Sec71 and Ubp2 in tunicamycin-induced ER stress response in the fission yeast.

Authors:  Merve Yemenici; Burcu Kartal Sural; Semian Karaer Uzuner; Bedia Palabiyik
Journal:  Mol Biol Rep       Date:  2022-04-26       Impact factor: 2.742

Review 4.  Using Drosophila to drive the diagnosis and understand the mechanisms of rare human diseases.

Authors:  Nichole Link; Hugo J Bellen
Journal:  Development       Date:  2020-09-28       Impact factor: 6.868

5.  Loss of SMPD4 Causes a Developmental Disorder Characterized by Microcephaly and Congenital Arthrogryposis.

Authors:  Pamela Magini; Daphne J Smits; Laura Vandervore; Rachel Schot; Marta Columbaro; Esmee Kasteleijn; Mees van der Ent; Flavia Palombo; Maarten H Lequin; Marjolein Dremmen; Marie Claire Y de Wit; Mariasavina Severino; Maria Teresa Divizia; Pasquale Striano; Natalia Ordonez-Herrera; Amal Alhashem; Ahmed Al Fares; Malak Al Ghamdi; Arndt Rolfs; Peter Bauer; Jeroen Demmers; Frans W Verheijen; Martina Wilke; Marjon van Slegtenhorst; Peter J van der Spek; Marco Seri; Anna C Jansen; Rolf W Stottmann; Robert B Hufnagel; Robert J Hopkin; Deema Aljeaid; Wojciech Wiszniewski; Pawel Gawlinski; Milena Laure-Kamionowska; Fowzan S Alkuraya; Hanah Akleh; Valentina Stanley; Damir Musaev; Joseph G Gleeson; Maha S Zaki; Nicola Brunetti-Pierri; Gerarda Cappuccio; Bella Davidov; Lina Basel-Salmon; Lily Bazak; Noa Ruhrman Shahar; Aida Bertoli-Avella; Ghayda M Mirzaa; William B Dobyns; Tommaso Pippucci; Maarten Fornerod; Grazia M S Mancini
Journal:  Am J Hum Genet       Date:  2019-09-05       Impact factor: 11.025

Review 6.  Membrane trafficking in health and disease.

Authors:  Rebecca Yarwood; John Hellicar; Philip G Woodman; Martin Lowe
Journal:  Dis Model Mech       Date:  2020-04-30       Impact factor: 5.758

Review 7.  ER-to-Golgi Trafficking and Its Implication in Neurological Diseases.

Authors:  Bo Wang; Katherine R Stanford; Mondira Kundu
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

8.  Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling.

Authors:  Zhixiong Liu; Minbiao Yan; Wanying Lei; Rencai Jiang; Wenxiu Dai; Jialin Chen; Chaomeng Wang; Li Li; Mei Wu; Ximing Nian; Daopeng Li; Di Sun; Xiaoqi Lv; Chaoying Wang; Changchuan Xie; Luming Yao; Caiming Wu; Jin Hu; Naian Xiao; Wei Mo; Zhanxiang Wang; Liang Zhang
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 14.808

9.  Escalated (Dependent) Oxycodone Self-Administration Is Associated with Cognitive Impairment and Transcriptional Evidence of Neurodegeneration in Human Immunodeficiency Virus (HIV) Transgenic Rats.

Authors:  Yu Fu; Irene Lorrai; Barry Zorman; Daniele Mercatelli; Chase Shankula; Jorge Marquez Gaytan; Celine Lefebvre; Giordano de Guglielmo; Hyunjae Ryan Kim; Pavel Sumazin; Federico M Giorgi; Vez Repunte-Canonigo; Pietro Paolo Sanna
Journal:  Viruses       Date:  2022-03-24       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.